6 results match your criteria: "Hospital Álvarez[Affiliation]"
Arch Bronconeumol
July 2021
Department of Respiratory Medicine - Adult Cystic Fibrosis Unit, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; CIBER Enfermedades Respiratorias (Ciberes), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Arch Bronconeumol (Engl Ed)
November 2020
Department of Respiratory Medicine - Adult Cystic Fibrosis Unit, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; CIBER Enfermedades Respiratorias (Ciberes), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Respir Med
June 2021
Department of Respiratory Medicine, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain; CIBER Enfermedades Respiratorias, Barcelona, Spain; Department of Respiratory Medicine, Vall d'Hebron Research Institute, Barcelona, Spain. Electronic address:
Background: The occurrence of radiological opacities post-transbronchial cryobiopsy may pose serious difficulties in differential diagnosis and management of lung allografts. This prospective study evaluated the frequency, characteristics, and evolution of new lung opacities after performing transbronchial cryobiopsy.
Methods: From February 2018 to June 2018, 22 of 51 consecutive patients with an indication for transbronchial cryobiopsy underwent computed tomography (CT) of the thorax before and at 1, 4, and 8 weeks post-cryobiopsy.
Biochim Biophys Acta
November 2016
Department of Cell & Molecular Biology, Pontificia Universidad Catolica de Chile, Santiago 8331010, Chile; CARE-Chile-UC, Pontificia Universidad Catolica de Chile, Santiago 8331010, Chile. Electronic address:
Background: Niemann-Pick type C (NPC) disease is characterized by lysosomal accumulation of cholesterol. Interestingly, NPC patients' brains also show increased levels of amyloid-β (Aβ) peptide, a key protein in Alzheimer's disease pathogenesis. We previously reported that the c-Abl tyrosine kinase is active in NPC neurons and in AD animal models and that Imatinib, a specific c-Abl inhibitor, decreased the amyloid burden in brains of the AD mouse model.
View Article and Find Full Text PDFGen Hosp Psychiatry
December 2017
Endocrinology and Nutrition, Malaga Regional University Hospital, Instituto de Biomedicina de Málaga (IBIMA), Málaga University, Spain; CIBERDEM, CIBER of Diabetes and Associated Metabolic Diseases (Instituto de Salud Carlos III: CB07/08/0019). Electronic address:
Background: Cystic fibrosis (CF) is a chronic disease with an impact on the quality of life. Self-reported symptoms of depression and anxiety were assessed in the Spanish cohort of the International Epidemiological Study on Depression and Anxiety in patients with CF (International Depression-Anxiety Epidemiological Study) and their relationship with health status and health-related quality of life (HRQoL) was evaluated.
Methods: This cross-sectional study recruited adult patients with CF at 10 Spanish centers.
Respir Med
July 2015
Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Alfred-Herrhausen-Straße 50, D-58448 Witten, Germany; Philipp Klee-Institute for Clinical Pharmacology, Helios Clinic Wuppertal, Heusnerstr. 40, D-42283 Wuppertal, Germany. Electronic address:
Background: For patients with asthma, COPD, or asthma-COPD overlap syndrome (ACOS), inter-country comparisons of seasonal changes in drug prescriptions are scarce or missing. Hence, we aimed to compare seasonal changes in prescription rates of long-acting beta-2-agonist (LABA) in four European countries.
Methods: A common study protocol was applied to six health care databases (Germany, Spain, the Netherlands (2), and the UK (2)) to calculate age- and sex-standardized point prevalence rates (PPRs) of LABA-containing prescriptions by the 1st of March, June, September, and December of each year during the study period 2002-2009.